Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. - Wikidata - awgldk - TriplyDB

Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.

Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.

http://www.wikidata.org/entity/Q38951195

about

Gastric Cancer in the Era of Precision Medicine.Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis.Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis.Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy.Molecular Testing for Gastrointestinal Cancer.In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.Chemotherapy for advanced gastric cancer: future perspective in Japan.Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-analysis Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.Actionable gene-based classification toward precision medicine in gastric cancer.Downregulation of Piwil3 suppresses cell proliferation, migration and invasion in gastric cancer.Next generation sequencing-based emerging trends in molecular biology of gastric cancer.Biomarkers of gastric cancer: Current topics and future perspective

P2860

Q33600457-82E8ECC7-DF48-46C2-8FDB-D5E4E64CFAE1 Q33873653-B12F17AF-AC73-45ED-9490-7E25FD17E81C Q33888813-F24FF5A8-F3C3-434F-96FA-B719A6454D59 Q36670779-E17C7D2D-F484-4B11-AC0B-D07837DC0FCC Q37342442-D8F60449-7B77-4C58-A4CA-29A929A0188C Q37536970-6E52E964-F10B-4E02-8A30-3AE639F97B91 Q37710556-EF8B378A-A730-4BE4-8D18-EC6AAA3CCED0 Q38602669-94D39DB7-625C-4B0B-812E-3CB6A1F0BD33 Q38815071-81F650BF-7E54-4E56-B782-7BC7DE2308EA Q39038994-41B91C71-8262-4DF3-8905-8A84A1395D8A Q40581214-B12C64AE-DC2C-4C8B-97AC-60182926D2E9 Q42050401-78BDA089-A200-4017-8E14-B30F61A3DFBA Q44288144-C938D59E-8725-48DF-BDDE-CC6E67F05989 Q44846648-F64FA52B-7889-41E2-AD13-9993A4A2803C Q47113548-82838772-4A29-431A-9076-190C06FC7345 Q47860797-932A01A2-09CB-4F89-BFD6-AF58E3F9D710 Q54261019-49D870D6-C53E-407F-9297-0B41F69830E8 Q57176090-EAB4B540-637A-4242-B08F-A944D833BA25

P2860

Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.

http://www.wikidata.org/entity/Q38951195

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Comprehensive analyses using n ...... nt in advanced gastric cancer.

@en

type

label

Comprehensive analyses using n ...... nt in advanced gastric cancer.

@en

prefLabel

Comprehensive analyses using n ...... nt in advanced gastric cancer.

@en

P1433

Q38951195-8B639CF9-A3F7-4E2F-AADE-6F3DDD1BF262

P1476

Q38951195-DE2EE441-E34F-4E06-BF27-5A3F7E955E68

P2093

Q38951195-19CAC2F6-A4DE-48DA-BCEC-B93FB79C7E9C

Q38951195-985FCFA6-4DFA-4BAD-95F1-72EC87DD01B4

Q38951195-C47FDB0D-0033-4899-AF0C-85F7BE77C4FE

Q38951195-DB157754-BA34-4142-BE5A-D53B39E7B256

Q38951195-E48A2F61-5596-4450-BD66-900122085996

Q38951195-EC2510D4-1A59-479E-A507-4EBF8C0A140D

Q38951195-EEAE4BAD-1847-43B9-A602-FA539DAEA48D

Q38951195-F48450C0-1EB8-49A2-BB5B-0FA44F9E4ED1

Q38951195-FBD2DD64-8B2B-46A6-B3D6-432774EDF899

P2860

Q38951195-1E680F72-38A5-4EF5-84A9-77DFCFCE4753

Q38951195-20E5C439-5E73-405B-BC2D-6A1AED92B279

Q38951195-32D4F07B-B21F-4672-B6DE-90940D0259C8

Q38951195-3D78569E-450D-45DC-9914-B96F2CAEB15F

Q38951195-40821E2C-2D85-4A5E-ABA3-708B7418ADF4

Q38951195-5A825302-14A7-4677-9AF2-84ED721772D4

Q38951195-629C0528-6C1F-4660-ABB8-C8283B4A9018

Q38951195-689012B7-6DD1-4EFA-806A-F64EE6F277DD

Q38951195-70BB670C-C4B7-4B90-80F9-7EC448FE37ED

Q38951195-7557BE6E-BEEE-4AE1-81D4-CE6BE9548E09

P304

Q38951195-35E9389D-2FFB-46BD-93C0-D2EF3B6B4B8B

P31

Q38951195-7BE261D5-4E6C-4900-A5A9-E2CF75DE92AD

P356

Q38951195-280FD66F-E576-4E0C-B094-3E3636A43A36

P433

Q38951195-46F78D80-0EE4-40A4-B3AE-C9BA27D44169

P478

Q38951195-18ABB21F-6A60-4FD1-A5D2-4028571790B8

P50

Q38951195-2AF7044B-CF7D-4DFD-989D-20A8668A186D

P577

Q38951195-1B077128-1C8D-459F-8883-26904F298B26

P698

Q38951195-303C0E43-F7EF-49A8-9996-77F1E406C045

P921

Q38951195-E12B153A-8938-4287-BA90-8BBF859531FA

P356

P1433

Annals of Oncology

P1476

Comprehensive analyses using n ...... nt in advanced gastric cancer.

@en

P2093

A Nagatsuma

http://www.w3.org/2001/XMLSchema#string

A Ochiai

http://www.w3.org/2001/XMLSchema#string

A Ohtsu

http://www.w3.org/2001/XMLSchema#string

S Yamashita

http://www.w3.org/2001/XMLSchema#string

T Doi

http://www.w3.org/2001/XMLSchema#string

T Kuwata

http://www.w3.org/2001/XMLSchema#string

T Niwa

http://www.w3.org/2001/XMLSchema#string

T Yoshino

http://www.w3.org/2001/XMLSchema#string

Y Kuboki

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Comprehensive molecular characterization of gastric adenocarcinoma

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

P304

127-133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDV508

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Toshikazu Ushijima

P577

2015-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26489445

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry